NICE does not accept Keytruda (pembrolizumab) as a cost effective treatment for urothelial (bladder) cancer.- Merck Inc.

The National Institute for Health and Care Excellence (NICE) in preliminary guidance has decided that Keytruda ( pembrolizumab) from Merck Inc., is not cost effective as a treatment for Urothelial (Bladder) Cancer. NICE accepted that the drug significantly improved overall survival (extension of lives by more than three months) compared to docetexel and paclitaxel chemotherapy but its cost effectiveness is uncertain as its economic modelling is unclear. A final determination will be made in November.